The NHS can rightly be proud that a small number of patients in England will be the first in Europe to have routine access to this highly complex technology. But the challenges presented by exciting new treatments like CAR T won't go away. Today's good news should be just the start, no...
One CAR T cell therapy, called tisagenlecleucel (Kymriah), was approved for some children and young adults with leukaemia. But a second, called axicabtagene ciloleucel (Yescarta), was rejected due to uncertainty about the treatment's long-term benefits. Yescarta is used to treat some typ...
NHS England has announced a deal with Gilead, AbbVie, and Merck, Sharpe and Dohme (MSD), in a bid to eliminate hepatitis C from the country.